The new company, EA Pharma, will be held at 60 % by Eisai and 40 % by Ajinomoto and start operation from April 2016. Products will include Ajinomoto’s branched-chain amino acid formulations, Eisai’s proton pump inhibitors, but also antibodies intended for the treatment of Crohn’s disease which are currently under development

Ajinomoto press release, Oct. 15, 2015